Celmatix and Aché Laboratórios Announce Collaboration to Investigate a Novel Melatonin Receptor Agonists for Women’s Health
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug. The innovative investigational product has the potential to revolutionize fertility treatments. The announcement coincides with the annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), currently underway in Copenhagen, Denmark.
NEW YORK--(BUSINESS WIRE)--Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors. Dr. Herbert joins as the company announces the launch of a novel drug development program supporting ovarian health throughout a women’s lifespan adding to their next generation of interventions and advancements in women’s health.
Celmatix Launches Novel PCOS Drug Program
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a fourth milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a second drug program, centered around a novel Celmatix-identified drug target, into hit-identification.
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced that Craig Bolton has been appointed as General Counsel. Bolton joins the Celmatix executive team after representing the biotech as outside counsel since 2019 and will play a critical role in supporting the company in ongoing therapeutic pipeline expansion and progress of their lead AMHR2 agonist program.
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced that Reproductive Endocrinology pioneer Dr. Bart CJM Fauser, MD, PhD, FRCOG, will join and Chair its Scientific Advisory Board and newly-formed Clinical Trial Steering Committee. This update follows the company’s recent announcement of the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. Additionally, the company announced today that the same novel compound has also achieved an important in vivo PK/PD milestone and demonstrates therapeutically-relevant ovarian responses in a rodent model.
NEW YORK--(BUSINESS WIRE)--Celmatix Inc. a biotechnology company focused on ovarian biology, today announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug. The program, which was a product of Celmatix’s decade-long focus on identifying novel biomarkers and drug targets for women’s health, has a planned first clinical indication in the prevention of premature menopause in women undergoing chemotherapy. Loss of ovarian function and menopause are accelerated by approximately 1.5 years for each month a woman receives chemotherapy treatment.
Evotec partner Celmatix achieves milestone for PCOS drug programme
NEW YORK--(BUSINESS WIRE)--Celmatix Inc., a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug program, centered around a novel Celmatix-identified drug target, into hit-identification.